Legal Representation
Attorney
Ronald M. Kachmarik
USPTO Deadlines
Next Deadline
1055 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-09-27)
Due Date
September 27, 2028
Grace Period Ends
March 27, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 19, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Feb 14, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Jan 25, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Jan 25, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Dec 27, 2022 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Sep 27, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 27, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 19, 2022 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Jul 12, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 12, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 29, 2022 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Jun 29, 2022 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jun 22, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 9, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 8, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 7, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 7, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 25, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| May 8, 2022 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| May 4, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| May 4, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Mar 25, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Mar 24, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 17, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 12, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Nov 8, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 5, 2021 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED | Loading... |
| Oct 28, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases, gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; organic biological preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; diagnostic preparations for medical use; diagnostic reagents for medical use
Class 042
Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical products, in particular conducting clinical trials for others for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely providing information, results and data relating to scientific or medical research and development of pharmaceutical products, especially from an online searchable database; medical and scientific research, namely conducting clinical trials for others; pharmaceutical and biological development and research services for third parties; clinical research for others in the field of pharmaceuticals and medicines; evaluation of the efficacy of pharmaceutical products
Additional Information
Design Mark
The mark consists of the stylized word "ELATIVE" with the letters "ELATI" and the last letter "E" in blue and the letter "V" in orange.
Color Claim
The color(s) blue and orange is/are claimed as a feature of the mark.
Classification
International Classes
005
042